NCT05494541View on ClinicalTrials.gov

Characteristics of Patients With Sickle Cell Disease

CompletedOBSERVATIONAL
Enrollment

540

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

October 27, 2021

Study Completion Date

October 27, 2021

Conditions
Sickle Cell Disease
Interventions
OTHER

Crizanlizumab

Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.

Trial Locations (1)

07936-1080

Novartis Investigative Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY